Home
PRQR

PRQR

ProQR Therapeutics N.V.

as of 11-28-2025 12:33pm EST

$2.34

$0.02

-1.06%

Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.

Chart Type:

Time Range:

Founded:	2012	Country:	Netherlands
Employees:	N/A	City:	N/A
Market Cap:	250.7M	IPO Year:	2014
Target Price:	$8.14	AVG Volume (30 days):	348.1K
Analyst Decision:	Strong Buy	Number of Analysts:	7
Dividend Yield:	N/A	Dividend Payout Frequency:	N/A
EPS:	-0.48	EPS Growth:	N/A
52 Week Low/High:	$1.07 - $3.97	Next Earning Date:	11-06-2025
Revenue:	$18,859,556	Revenue Growth:	-12.57%
Revenue Growth (this year):	-14.2%	Revenue Growth (next year):	-22.80%

AI-Powered PRQR Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold

Model Accuracy: 71.03%

71.03%

Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

View Full PRQR Forecast & Prediction with Hourly Data

Compare PRQR vs Leading Stocks

See how PRQR stacks up against similar companies in the market

Share on Social Networks:

Tools & Resources

Enhance your trading experience with our free tools

Free PRQR Stock Widget

Embed our interactive stock ticker widget on your website for real-time updates.

Free Tool

Stock Alerts on Telegram

Get instant notifications, market insights, and expert analysis delivered to your phone.

Live Updates

Disclaimer

The information presented on this page, "PRQR ProQR Therapeutics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.